The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis

NCT ID: NCT02614300

Last Updated: 2015-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pulmonary rehabilitation programs are part of the multidisciplinary treatment of some chronic respiratory diseases such as COPD (chronic obstructive pulmonary disease). Although clinical guidelines of other diseases such as non-cystic fibrosis bronchiectasis (nCFBE) discuss the benefits of these programs in quality of life and exercise tolerance, evidence of such intervention in nCFBE patients is insufficient. Longer studies are needed with larger sample sizes and optimized to maximize the response and maintain long-term benefits. The present study aims to examine the effects in exercise tolerance of a pulmonary rehabilitation program combined with respiratory physiotherapy in patients with nCFBE. It is a randomized controlled clinical trial with a total duration of 24 months. The intervention will be performed during 12 weeks and then will be a period of 12 months of maintenance. This is a multicenter study involving the following Hospitals: Hospital Clinic, Hospital la Plató and Hospital del Mar of Barcelona, Hospital Josep Trueta of Girona, Royal Infirmary of Edinburgh and Fondazione Maugeri di Lumezzane of Italy. Subjects will be randomized into three groups in a ratio (1: 1: 1) (1) Pulmonary Rehabilitation (2) Chest Physiotherapy and (3) Pulmonary Rehabilitation + Chest Physiotherapy. Hospital la Plató from Barcelona will be responsible for carrying out the Control Group. The primary endpoint will be the test of "endurance shuttle walk test".

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-cystic Fibrosis Bronchiectasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary Rehabilitation

These sessions will be individually designed and they will be a combination of global aerobic interval training using a cycloergometer. The aim is to achieve a training intensity of 80% HR or greater of the obtained during the ISWT. This intensity will be progressively increased during the firsts four weeks until achieving the target. The duration will be of about 45 minutes per session. Oxygen Saturation, HR and Borg scale for dyspnoea and fatigue will be measured before, during and at the end of the session in order to monitories the effort.

Group Type ACTIVE_COMPARATOR

Pulmonary Rehabilitation

Intervention Type OTHER

The patient will come 3 times per week during 12 weeks Each session 45min

Chest Physiotherapy

The ELTGOL technique ("total slow expiration with glottis open in lateral decubitus") for airways clearance will be used in order to move respiratory secretions from the distal bronchial tree. It will be applied during 15 minutes each side (right and left lungs) assuming an approximate session length of 30 minutes. The patient could perform the cough technique when it's necessary.

Group Type ACTIVE_COMPARATOR

Chest Physiotherapy

Intervention Type OTHER

The patient will come 3 times per week during 12 weeks Each session 30min

Pulmonary Rehabilitation and Chest Physiotherapy

This group will perform a combination of the two programs in the same session with a total duration of 1h and 15 minutes. The session will be divided in different parts: First, we will execute 15min of chest physiotherapy (7.5min for each side); second, the pulmonary rehabilitation session (45min) and finally, another 15min of chest physiotherapy (7.5min for each side). The patient will have a rest when it's necessary and we will continue with the session when there is a decrease of 2 points in the Borg scale.

Intensity of physiotherapy exercises and drainage techniques will be maintained similar to the PR and CP programs.

Group Type ACTIVE_COMPARATOR

Pulmonary Rehabilitation and Chest Physiotherapy

Intervention Type OTHER

The patient will come 3 times per week during 12 weeks Each session 1h15min

Control Group

For the control group, participants will attend educational sessions to improve patients' understanding and awareness of the respiratory diseases. These sessions will be performed at beginning and at 12 weeks by the physiotherapist and the pulmonologist.

The physiotherapist will also do monthly telephone calls for patient's monitoring.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pulmonary Rehabilitation and Chest Physiotherapy

The patient will come 3 times per week during 12 weeks Each session 1h15min

Intervention Type OTHER

Pulmonary Rehabilitation

The patient will come 3 times per week during 12 weeks Each session 45min

Intervention Type OTHER

Chest Physiotherapy

The patient will come 3 times per week during 12 weeks Each session 30min

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 50-80 years;
* No performing regular physiotherapy treatment or physical training (≤ 1 time/week);
* Stable disease \[no changes in the chronic therapy (both inhaled and systematic) in the usual respiratory symptoms (according to the medical evaluation) and spirometry in the last 4 weeks prior to study recruitment\];
* Regular cough and expectoration;
* Ability to follow the exercise program;
* Ability to perform all clinical tests, to understand the process and the purposes of the study;
* A history of at least 2 exacerbations during the previous year requiring antibiotic treatment and;
* Signed informed consent.

Exclusion Criteria

* Active smokers, ex-smokers of less than 1 year prior to recruitment and/or a history of \>20 smoking packs/year;
* FEV1 \<30% or/and TLC\<40% ;
* Diagnosis of cystic fibrosis, sarcoidosis, pulmonary fibrosis, active tuberculosis or non tuberculosis mycobacterial infection,
* Diagnosis of asthma or COPD as a primary respiratory disease and associated secondary bronchiectasis,
* Patients with unstable cardiac disease or locomotor difficulties that preclude exercise (eg, severe arthritis or severe peripheral vascular disease);
* Chronic respiratory failure and/or oxygen therapy;
* Frequent haemoptysis (≥ 2 times/month);
* Participation in a PR program during the year prior to inclusion or during the study protocol;
* Participation in a CP program during 1 month prior to inclusion;
* Any physical and psychological disorder that interferes with protocol compliance;
* Participation in a clinical trial implying any change in usual pharmacological treatment in the last 6 months before recruitment;
* Being on the waiting list for lung transplantation or have been transplanted.
Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sociedad Española de Neumología y Cirugía Torácica

OTHER

Sponsor Role collaborator

Hospital Clinic of Barcelona

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eva Polverino

Specialist in Respiratory Diseases

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Victoria Alcaraz, Physiotherapist

Role: CONTACT

+34 932275400 ext. 2333

Eva Polverino, Medical Doctor

Role: CONTACT

+34 932275549

References

Explore related publications, articles, or registry entries linked to this study.

Herrero-Cortina B, Alcaraz-Serrano V, Torres A, Polverino E. Reliability and Minimum Important Difference of Sputum Weight in Bronchiectasis. Respir Care. 2020 Oct;65(10):1478-1487. doi: 10.4187/respcare.07175. Epub 2020 Feb 18.

Reference Type DERIVED
PMID: 32071136 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PulmRehab_NCFBE

Identifier Type: -

Identifier Source: org_study_id